Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed its reacquisition from GlaxoSmithKline (GSK) of all rights to Adolor’s FDA-approved product ENTEREG® (alvimopan). “With GSK’s assistance, we are well-positioned for a smooth and timely transition of all ENTEREG-related efforts to Adolor, as planned,” said Michael D. Adelman, Vice President, Marketing and Sales. “We have completed the expansion of our field sales force and our representatives are in the field calling on customers. We have extensive knowledge of this marketplace, and are excited to continue supporting Health Care Provider efforts to accelerate patients’ gastrointestinal recovery and hospital discharge following bowel resection surgery.” About ENTEREG Adolor markets and sells ENTEREG in the United States. ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available only for short-term (15 doses) use in hospitalized patients. Only hospitals that have registered in and met all of the requirements for the ENTEREG Access Support and Education (E.A.S.E.) program may use ENTEREG. For more information on ENTEREG, including its full prescribing information, the Boxed Warning regarding short-term hospital use and the E.A.S.E.® Program, visit www.ENTEREG.com. About Adolor Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products. The Company's lead development program compound is ADL5945, a novel mu opioid receptor antagonist being developed for chronic OIC that demonstrated positive results in Phase 2 trials. The Company also has several earlier-stage compounds under development for the management of pain and CNS disorders. For more information, visit www.adolor.com. Forward-Looking StatementsThis press release, and oral statements made with respect to information contained in this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements provide Adolor’s current expectations or forecasts of future events.These may include statements regarding market prospects for ENTEREG; the development of potential pharmaceutical products, including ADL5945; interpretation of clinical results; prospects for regulatory approvals; anticipated scientific progress on Adolor’s research programs; and other statements regarding matters that are not historical facts.You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning or that otherwise express contingencies, goals, targets or future development.These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, that could cause actual results and developments to differ materially from those expressed or implied in such statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries, as well as more specific risks and uncertainties facing Adolor such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission.Adolor urges you to carefully review and consider the disclosures found in its filings which are available at www.sec.gov and from Adolor at www.adolor.com.Given the uncertainties affecting pharmaceutical companies such as Adolor, any or all of these forward-looking statements may prove to be incorrect.Therefore, you should not rely on any such factors or forward-looking statements.Adolor undertakes no obligation to publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise, except as may be required by law.This press release is available on the website http://www.adolor.com.